Taisho Licenses Kaigene’s KG006 FcRn Inhibitor in Japan

Taisho Pharmaceutical has secured exclusive rights to develop, register and commercialize Kaigene’s KG006, a next-generation FcRn inhibitor, in Japan under a new licensing agreement that could generate approximately $356 million in upfront and milestone payments for the US biotechnology company.

Kaigene announced the agreement with Japanese pharmaceutical company Taisho Pharmaceutical on July 30, 2026. Under the deal, Taisho will take responsibility for the clinical development, regulatory approval and commercialization of KG006 in Japan, giving Kaigene an established local partner to advance the drug in one of Asia’s major pharmaceutical markets.

Kaigene will receive a one-time upfront payment of $5 million under the agreement. The company is also eligible to receive up to a combined $22 million and ¥57.5 billion, equivalent to approximately $351 million, in development, regulatory and sales milestone payments. In addition, Kaigene will receive tiered royalties on net sales of KG006 in Japan.

KG006 is a next-generation human neonatal Fc receptor, or hFcRn, inhibitor being developed by Kaigene for autoimmune diseases. The FcRn pathway is involved in regulating immunoglobulin G, or IgG, antibodies in the body, making it an important target for drug developers working on antibody-mediated autoimmune disorders.

The licensing agreement strengthens Kaigene’s existing global development strategy for KG006. Celltrion currently holds global development and commercialization rights for the drug outside Greater China and Japan. The Taisho agreement therefore adds a dedicated Japanese partner while allowing the companies to maintain the broader international collaboration.

The deal could also lead to closer cooperation between Taisho, Kaigene and Celltrion as the KG006 clinical program advances. Subject to further clinical and regulatory planning, Taisho is expected to participate in a planned Phase 3 multi-regional clinical trial, or MRCT, led by Celltrion.

The proposed three-way collaboration is expected to provide a framework for coordinating KG006 development across multiple regions. By combining Kaigene’s drug development expertise, Celltrion’s global capabilities and Taisho’s experience in Japan, the companies aim to streamline the clinical development process and potentially accelerate the timeline toward regulatory submissions and commercialization.

Taisho brings significant experience in the autoimmune disease market and in the development and commercialization of biologic medicines. The company has extensive experience with Nanozora, an anti-TNF VHH antibody therapeutic used to treat rheumatoid arthritis in Japan. That background could support Taisho’s efforts to advance KG006 through clinical development and prepare for a potential commercial launch in the Japanese market.

For Taisho, the agreement expands its pipeline of innovative therapies for autoimmune diseases and provides access to a next-generation FcRn inhibitor. FcRn-targeted medicines have attracted growing attention from pharmaceutical and biotechnology companies because of their potential to reduce disease-driving antibodies in patients with autoimmune disorders.

For Kaigene, securing Taisho as its Japanese partner represents another step toward establishing KG006 as a global development program. The company is seeking to combine the capabilities of multiple partners to accelerate clinical development and explore the potential of KG006 across several autoimmune indications.

Kaigene CEO and founder Minjae Shin said the partnership brings together complementary expertise and could help speed up clinical trials and market launches within the companies’ respective territories. He also highlighted the possibility of studying KG006 in additional high-value indications as the development program progresses.

The next major milestone for KG006 will be its continued clinical development and the planned Phase 3 program. The success of the drug will ultimately depend on clinical trial results and regulatory decisions in Japan and other markets. However, the new agreement gives Kaigene a strong local partner in Japan while creating the potential for coordinated development with Celltrion across multiple territories.

With Taisho responsible for KG006 in Japan and Celltrion continuing its role in global development outside Greater China and Japan, Kaigene is building a broader international commercialization strategy for the FcRn inhibitor. The partnership also highlights continued industry interest in FcRn as a therapeutic target for autoimmune diseases.